Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Parkinson's and Alzheimer's that showed remarkable weight loss in Phase 2 trials. Now being developed specifically for obesity.
A modified fragment of human growth hormone (amino acids 177-191) originally developed as an anti-obesity agent. Targets fat metabolism without the growth-promoting effects of full HGH.
Inhibits reuptake of serotonin, norepinephrine, and dopamine, reducing appetite and increasing energy expenditure through central nervous system modulation. Different mechanism than GLP-1 agonists.
Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) by mimicking the fat-reducing action of natural growth hormone without affecting blood sugar or tissue growth.
- Weight management (investigational)
- Appetite suppression
- Metabolic rate enhancement
- Fat loss
- Metabolic health
- Body composition improvement
- Cartilage repair (emerging research)
- Increased heart rate
- Dry mouth
- Insomnia
- Constipation
- Potential cardiovascular concerns
- Not yet approved — full safety profile unknown
- Limited efficacy data in humans
- Injection site reactions
- Headaches
- Phase 2 trials showed modest results
Phase 3 clinical trials ongoing. Phase 2 showed up to 12.8% body weight loss at 24 weeks. Approved in Mexico (2024). Not FDA-approved in the US.
Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Previously reached Phase 2 clinical trials for obesity but was not pursued further by the original developer. Available through licensed 503A compounding pharmacies with a physician prescription.
- Tesofensine for treatment of obesity
2008 · PubMed
- AOD9604 - a novel anti-obesity drug
2001 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.